Emerging roles of PKM2 in cell metabolism and cancer progression

Trends in Endocrinology and Metabolism

Volumn 23, Issue 11, 2012, Pages 560-566

  Luo, Weibo ^a   Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LACTIC ACID; PYRUVATE KINASE; PYRUVATE KINASE M2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACETYLATION; ALLOSTERISM; CANCER CELL; CANCER GROWTH; CATALYSIS; CELL METABOLISM; CELL PROLIFERATION; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; HOMEOSTASIS; HUMAN; HYDROXYLATION; LIPOGENESIS; NONHUMAN; OXIDATION REDUCTION STATE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SUMOYLATION;

ANIMALS; CARRIER PROTEINS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HUMANS; LACTIC ACID; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; OXIDATIVE STRESS; PYRUVATE KINASE; THYROID HORMONES;

EID: 84867140008     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.06.010     Document Type: Review

References (64)

1. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
2. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
3. Steck T.L., et al. Glycolysis in chick embryo cell cultures transformed by Rous sarcoma virus. Cancer Res. 1968, 28:1611-1619.
4. Singh V.N., et al. Alterations in glucose metabolism in chick-embryo cells transformed by Rous sarcoma virus: intracellular levels of glycolytic intermediates. Proc. Natl. Acad. Sci. U.S.A. 1974, 71:4129-4132.
5. Carroll R.C., et al. Reversion of transformed glycolysis to normal by inhibition of protein synthesis in rat kidney cells infected with temperature-sensitive mutant of Rous sarcoma virus. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:5015-5019.
6. Dewan J.G., Green D.E. Coenzyme factor - a new oxidation catalyst. Biochem. J. 1938, 32:626-639.
7. Lunt S.Y., Vander Heiden M.G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 2011, 27:441-464.
8. Hirschhaeuser F., et al. Lactate: a metabolic key player in cancer. Cancer Res. 2011, 71:6921-6925.
9. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
10. Semenza G.L., Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 1992, 12:5447-5454.
11. Epstein A.C., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54.
12. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30:393-402.
13. Semenza G.L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 2010, 20:51-56.
14. Semenza G.L. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J. Bioenerg. Biomembr. 2007, 39:231-234.
15. Kim J.W., et al. Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol. Cell. Biol. 2004, 24:5923-5936.
16. Kim J.W., et al. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 2007, 27:7381-7393.
17. Bluemlein K., et al. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2011, 2:393-400.
18. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 2011, 43:969-980.
19. Imamura K., Tanaka T. Multimolecular forms of pyruvate kinase from rat and other mammalian tissues. I. Electrophoretic studies. J. Biochem. 1972, 71:1043-1051.
20. Friesen R.H., et al. Allostery in rabbit pyruvate kinase: development of a strategy to elucidate the mechanism. Biochemistry 1998, 37:15266-15276.
21. Noguchi T., et al. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem. 1986, 261:13807-13812.
22. David C.J., et al. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010, 463:364-368.
23. Clower C.V., et al. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1894-1899.
24. Chen M., et al. Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins. Nat. Struct. Mol. Biol. 2012, 19:346-354.
25. Wang Z., et al. Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons. J. Mol. Cell. Biol. 2012, 4:79-87.
26. Discher D.J., et al. Hypoxia regulates β-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J. Biol. Chem. 1998, 273:26087-26093.
27. Luo W., et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011, 145:732-744.
28. Sun Q., et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4129-4134.
29. Panasyuk G., et al. PPARgamma contributes to PKM2 and HK2 expression in fatty liver. Nat. Commun. 2012, 3:672.
30. Garcia-Cao I., et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 2012, 149:49-62.
31. Kefas B., et al. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol. 2010, 12:1102-1112.
32. Wong T.S., et al. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int. J. Cancer 2008, 123:251-257.
33. Christofk H.R., et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452:181-186.
34. Dombrauckas J.D., et al. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005, 44:9417-9429.
35. Grüning N.M., et al. Pyruvate kinase triggers a metabolic feedback loop that controls redox metabolism in respiring cells. Cell Metab. 2011, 14:415-427.
36. Hitosugi T., et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2009, 2:ra73.
37. Ye J., et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:6904-6909.
38. Lv L., et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 2011, 42:719-730.
39. Kosugi M., et al. MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. PLoS ONE 2011, 6:e28234.
40. Mor I., et al. Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase. Oncogene 2011, 31:683-693.
41. Shimada N., et al. Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. Genes Cells 2008, 13:245-254.
42. Christofk H.R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
43. Luo W., Semenza G.L. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2011, 2:551-556.
44. D'Angelo G., et al. Hypoxia up-regulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses during reoxygenation. J. Biol. Chem. 2003, 278:38183-38187.
45. Semenza G.L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 2012, 33:207-214.
46. Hoshino A., et al. Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J. Biol. Chem. 2007, 282:17706-17711.
47. Steták A., et al. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res. 2007, 67:1602-1608.
48. Yang W., et al. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 2011, 480:118-122.
49. Gao X., et al. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 2012, 45:598-609.
50. Lee J., et al. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int. J. Biochem. Cell Biol. 2008, 40:1043-1054.
51. Novo E., Parola M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair 2008, 1:5.
52. Szatrowski T.P., Nathan C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991, 51:794-798.
53. Wellen K.E., Thompson C.B. Cellular metabolic stress: considering how cells respond to nutrient excess. Mol. Cell 2011, 40:323-332.
54. Anastasiou D., et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334:1278-1283.
55. Krüger A., et al. The pentose phosphate pathway is a metabolic redox sensor and regulates transcription during the antioxidant response. Antioxid. Redox Signal. 2011, 15:311-324.
56. Vander Heiden M.G., et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 2010, 79:1118-1124.
57. Chen J., et al. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 2011, 30:4297-4306.
58. Boxer M.B., et al. Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J. Med. Chem. 2010, 53:1048-1055.
59. Goldberg M.S., Sharp P.A. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J. Exp. Med. 2012, 209:217-224.
60. Shi H.S., et al. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci. 2010, 101:1447-1453.
61. Guo W., et al. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J. Cancer Res. Clin. Oncol. 2011, 137:65-72.
62. Rohwer N., Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat. 2011, 14:191-201.
63. Spoden G.A., et al. The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2. J. Cell. Biochem. 2009, 107:293-302.
64. Noguchi T., et al. The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J. Biol. Chem. 1987, 262:14366-14371.